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ABSTRACT 
Bone is an endocrine tissue expressing androgen and oestrogen receptors as well as steroid 
metabolizing enzymes. The bioactivity of circulating sex steroids is modulated by sex hormone-
binding globulin and local conversion in bone tissue, e.g. from testosterone to oestradiol by 
aromatase, or to dihydrotestosterone by 5α-reductase enzymes. Our understanding of the structural 
basis for gender differences in bone strength has advanced considerably over recent years due to 
increasing use of (high resolution) peripheral computed tomography. These microarchitectural 
insights form the basis to understand sex steroid influences on male peak bone mass and turnover in 
cortical vs. trabecular bone. Recent studies using Cre/LoxP technology have further refined our 
mechanistic insights from global knock-out mice into the direct contributions of sex steroids and their 
respective nuclear receptors in osteoblasts, osteoclasts, osteocytes and other cells to male 
osteoporosis. At the same time, these studies have reinforced the notion that androgen and 
oestrogen deficiency have both direct and pleiotropic effects via interaction with e.g. insulin-like 
growth factor 1, inflammation, oxidative stress, central nervous system control of bone metabolism, 
adaptation to mechanical loading, etc. This review will summarize recent advances on these issues in 
the field of sex steroid actions in male bone homeostasis. 
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1. INTRODUCTION 
Bone is an endocrine tissue sensitive to androgens and oestrogens.1 The epidemiology and clinical 
approach to male osteoporosis have recently been reviewed elsewhere.2 Here, we will review the 
literature on the role of sex steroids in male bone health and more specifically in osteoporosis, the 
most common metabolic bone disease. We will focus on human data with support from recent 
evidence from knock-out mouse models. The latter are covered in more detail elsewhere in this issue 
[Ref Zajac AJA]. 
 
1.1 Men contribute considerably to the disease burden of osteoporosis 
Although still perceived by the public, patients and most physicians as a typically female condition, 
men account for a substantial proportion of the burden of osteoporosis. At age 50, the remaining 
lifetime risk of osteoporotic fractures is 20-25% in Caucasian men versus 45-55% in women.2 About 
one third of the 9 million osteoporotic fractures worldwide occurs in men.3 For hip fractures, a review 
of worldwide epidemiological data recently showed that while incidence varied more than tenfold 
between countries, men almost invariably have twofold lower risk (except perhaps in regions where 
incidence is very low).4 Male osteoporosis is responsible for about 25% of the economic burden of 
osteoporosis in the United States ($ 17 billion total costs) and Canada (2.3 billion Canadian dollars).5-7 
Nevertheless, osteoporosis remains even more underdiagnosed and undertreated in men compared 
to women, regardless of whether it is evidenced by low bone mineral density (BMD),8 a low-energy 
fracture9, 10 or absolute 10 year fracture probability.11, 12 
 
1.2 Basic sex steroid physiology in relation to bone health 
1.2.1 Metabolism and regulation of circulating sex steroids 
Sex steroid serum concentrations are determined by their synthesis in the gonads and adrenals as 
well as by catabolic enzyme activity. Testosterone (T), the principal circulating androgen, can be 
aromatized to oestradiol (E2, the principal oestrogen) or 5α-reduced to dihydrotestosterone (DHT), a 
non-aromatizable androgen. Thus, in bone T may stimulate the androgen receptor (AR), either 
directly or as DHT, as well as oestrogen receptors (ER) following aromatization .13 
The synthesis of sex steroids is under hypothalamic-pituitary feedback control via gonadotropins 
(follicle stimulating hormone, FSH and luteinizing hormone, LH). Several high-profile reports have 
suggested that FSH contributes to hypogonadal bone loss in female rodents, 14, 15 but other groups 
have failed to confirm the presence of FSH receptors in bone cells or a physiological effect thereof.16-
19 Gonadotropin inhibition also does not seem to influence bone turnover markers independent of 
sex steroid levels in men. 20 
Serum bioactivity of sex steroids is restricted in humans by their high affinity binding to sex hormone-
binding globulin (SHBG). About 45% of testosterone (T), the principal circulating androgen, is bound 
to SHBG in normal men; only the non-SHBG-bound fraction is considered bioactive. Most of this 
fraction is bound non-specifically to albumin and other carrier proteins, while only about 2% of T and 
oestradiol (E2) and <1% of DHT circulates freely in normal men.21 According to the free hormone 
hypothesis however, this constitutes the most physiologically important fraction.22 Others have 
pointed to the limitations of this theory and have pleaded to “stop looking backwards” and focussing 
exclusively on free sex steroid levels. Indeed, even if only a small portion of the protein-bound sex 
steroids is physiologically active, it is likely to have more influence than the 1 to 2% that is free.23 
1.2.2 Sex steroid nuclear receptor signalling 
Sex steroids classically act via their nuclear receptors (NRs: AR, ERα and ERβ), which bind directly or 
indirectly via other proteins to cognate DNA response elements (AREs and EREs), recruit coactivators 
and other regulatory proteins, and influence gene transcription.24 Two types of AREs exist (classical 
and selective), but mice with abrogated AR binding to selective ARE only show a sex organ 
phenotype.25 Non-classical signalling pathways of these NRs have also been described but remain 
somewhat controversial (especially for AR). These have not yet been successfully translated 
(therapeutically) to studies in humans, and will therefore not be further discussed here. 
Androgen and oestrogen deficiency also have important indirect effects via other signalling pathways 
in bone (e.g. insulin-like growth factor I (IGF-1)26), potentially via AR and ER in other tissues like 
muscle, fat and the nervous system, or via e.g. decreased physical activity in AR knock-out (ARKO) 
mice27, 28. Therefore, caution needs to be exerted regarding the roles of AR and ER specifically in bone 
cells when interpreting the results of gonadectomy or ARKO/ERKO models. These limitations have 
been overcome recently using Cre/LoxP mouse models (see below). The fact that these cell-specific 
models show less dramatic bone phenotypes than their global ARKO/ERKO counterparts confirms the 
importance of pleiotropic actions of sex steroids on bone. 
 
2. STRUCTURAL BASIS OF MALE BONE STRENGTH 
The musculoskeletal system is sexually dimorphic, being on average (but obviously not in all cases) 
larger and more robust in men compared to women. Bone strength is determined by peak bone mass 
(PBM) acquisition in young adulthood and subsequent turn-over in different compartments (cortical 
and trabecular bone), resulting in gender differences in bone length, bone mineral density (BMD), 
geometry and microarchitecture. For other determinants like material properties, gender differences 
require further investigation. Osteoporotic fracture risk is not only determined by purely skeletal 
factors but also by risk of falls, which should also be evaluated and treated in osteoporotic men.29, 30  
In the following paragraphs, we will discuss the structural basis of male bone strength. It is well 
known that men have higher peak areal BMD (aBMD) in young adulthood and aBMD declines slower 
as they age.31 However, caution should be used because of the projectional nature of dual energy X-
ray absorptiometry (DXA), which leads to potential confounding by bone size, geometry and porosity 
rather than true volumetric density (vBMD). In this respect, quantitative computed tomography (qCT), 
especially high resolution peripheral qCT (HR-pqCT), has recently led to a major advance in our 
understanding of the gender dimorphism in the structural determinants of bone strengths. 
 
2.1 Bone size 
Men are on average taller due to the actions of sex steroids on the growth plate (see below). From a 
biomechanical point of view, longer bones (which are also wider and have greater bone mass) are 
more resistant to bending. However, several cohort studies have found a positive association 
between height and risk of low-energy fractures, although the results in men are scant and only 
bordered significance.32, 33 This may be explained by greater loads when falling from a larger height, 
longer arms of moment as well as by relatively thinner cortices and greater cortical porosity in larger 
bones, although definitive data in men are currently lacking.34 
 
2.2 Peak bone mass 
Bone mineral mass can be low in old age because insufficient PBM attainment during skeletal growth 
(modelling phase) or due to an imbalance in the normally coupled process of bone turnover 
(remodelling phase), either by excessive bone resorption or decreased bone formation. The risk of 
many chronic diseases which manifest in old age, including osteoporosis, is determined at least in 
part by childhood or even prenatal experiences. PBM is largely (60-80%) genetically determined, but 
the remainder is determined by environmental factors, some of which (e.g. maternal age and vitamin 
D status during pregnancy) are potentially amenable to interventions.35, 36 Theoretically, small 
increases in PBM translate into a large delay in osteoporosis onset,37 although it remains to be 
established whether bone mass increments early in life can be sustained into old age.38  
The age of PBM or peak bone density differs between studies and depends on the measured site. In a 
prospective study with 15 years of follow-up, BMC in boys plateaued first at the femoral neck, 
followed by the total hip, lumbar spine and whole body, respectively at the age of 2, 3, 4 and 6 years 
after peak height velocity (PHV, average age 14 in men).39 Hip aBMD decreases early after it peaks.40 
Longitudinal studies across a wider age range have however estimated that lumbar spine BMD may 
peak as late as age 33 and 40 in men and women, respectively. Bone area increments are followed 1-
2 years later by mineralization, and there are little differences between men and women when the 
age of PHV is used as the reference.41 The peripubertal years (age 12-16) contributed 33-46% to 
adult-level BMC, demonstrating the importance of this window of opportunity for interventions to 
optimize PBM.39 There is considerable variation in the timing of male puberty, but neither early nor 
late normal puberty seem to compromise PBM.42 
 
2.3 Bone geometry and microarchitecture 
Men develop wider bones even after adjustment for height because of greater periosteal apposition 
in the appendicular skeleton, whereas girls predominantly decrease their endosteal perimeter.1 As a 
result, cortical bone in men is placed further away from the neutral axis, providing greater resistance 
to bending, but no difference in size-independent biomechanical indices.43, 44 Bone width predicts 
fractures in older men independently of aBMD, and men with low bone width combined with BMD T-
scores < -1 have similar fracture incidence as men with T-scores < -2.45 
Recent, mostly cross-sectional studies using HR-pqCT have documented cortical and trabecular bone 
across the lifespan in more detail (Figure 1). 
At PBM, men have higher trabecular bone volume fraction (Fig. 1a) due to thicker (Fig. 1c), more 
plate-like trabeculae. On the other hand, cortical porosity is greater (not shown) and cortical vBMD 
slightly lower (Fig. 1f), while trabecular vBMD (not shown) and cortical thickness (Fig. 1e) are not yet 
greatly different.43, 46-48 Increasing cross-sectional area and cortical thickness, ongoing cortical 
mineralization and decreasing porosity contribute to ongoing aBMD and estimated strength increases 
during the third decade of life in men, whereas in women cortical perimeter and strength do not 
increase during young adulthood.40, 49  
Both cortical and trabecular vBMD losses are more pronounced with age in women, although rates of 
trabecular bone loss vary across sites.43, 50 With ageing, endocortical resorption outpaces periosteal 
apposition leading to a thinner cortex in both sexes, but older women show dramatically greater 
medullary expansion and thus cortical thinning (Fig. 1e and Figure 2).43, 51-53 This was nicely illustrated 
in one prospective pqCT study (Figure 2), which also demonstrated the limitations of capturing bone 
geometrical changes across the lifespan from cross-sectional data.51  
Cortical porosity is greater in young men but increases faster in women, especially after menopause, 
resulting in similar porosity after age 50.43, 44 Cortical vBMD decreases from midlife in women but 
only after age 75 in men, whereas trabecular bone loss starts almost immediately after PBM in both 
sexes (Fig. 1a) but more so in women, with acceleration during perimenopause.50, 53 Bone loss in men 
is more due to decreased formation rather than increased resorption, therefore trabeculae become 
thinner (Fig. 1c) but less perforated, disconnected and thus widely spaced (Fig. 1b,d) compared to 
postmenopausal women.46, 54 Poor trabecular microarchitecture predisposes men to multiple and 
severe vertebral and peripheral fractures.55 At the femoral neck, men have higher aBMD despite 
lower vBMD, due to greater length and femoral neck area, showing the importance of geometry over 
mineralization in the decreased hip fracture risk in men.56 This also explains why men and women 
have the same strength for the same femoral neck aBMD: because of the offsetting effects of higher 
bone area and lower vBMD in men.57  
In conclusion, detailed imaging techniques have greatly improved our understanding of the structural 
basis for gender differences in bone strength. How and to what extent sex steroids regulate this 
sexual dimorphism in cortical and trabecular bone will be discussed below. 
3. SEX STEROID SIGNALLING IS KEY TO MUSCULOSKELETAL SEXUAL DIMORPHISM 
Are gender differences in bone phenotype due to sex steroid signalling or other pathways? Sex 
steroids and especially oestrogens were once considered a central hub on which bone signalling 
pathways converged in both genders,58 but this unitary oestrogen-centric view has been modified.59, 
60 Both at peak bone mass (PBM) and during ageing, BMD, bone geometry, bone turn-over and 
skeletal muscle mass in men have now been associated with multiple hormones (e.g. IGF-1 and IGF 
binding proteins,61-64 endogenous PTH,63, 65 vitamin D,66, 67  thyroid hormone within the normal 
range68, 69), immunological and other pathways in bone (e.g. CRP70, RANK/RANKL/OPG71-73), oxidative 
stress and classical ageing pathways,60 etc. Mostly similar associations have however been reported 
in women, and a recent meta-analysis of genome-wide BMD association studies failed to identify any 
significant gene-by-sex interactions.74 Fundamental gender differences in key bone signalling 
pathways therefore seem unlikely. 
Conversely, the musculoskeletal system of transsexual men shows a dramatic shift from the female 
to male phenotype after ovariectomy and prolonged testosterone treatment.75 Similarly, XY women 
with complete androgen insensitivity syndrome due to inactivating AR mutations have reduced BMD 
and a bone geometry intermediate between male and female, and oestrogen treatment does not 
induce periosteal bone apposition in these subjects.76 BMD is however much lower in both XY and XX 
women with gonadal dysgenesis, implying that gonadal status or sex steroids are more important 
than chromosomal determinants.77 Overall, we can conclude that androgens (or androgen receptor 
mediated androgen action) are necessary for musculoskeletal sexual dimorphism in development and 
ageing, although they probably have important indirect actions on bone via aromatization, oxidative 
stress78, pro-inflammatory cytokines,79, 80 growth factors (e.g. transforming growth factor (TGF)-β, 
IGF-1),1, 26, 81, etc. 
 
 
4. SEX STEROID REGULATION OF MALE BONE METABOLISM 
4.1 Sex steroids control longitudinal bone size at the growth plate 
It is generally accepted that delayed oestrogen-mediated closure of epiphyseal growth plate cartilage 
contributes to greater bone length in men. Testosterone on the other hand probably also stimulates 
height velocity mainly via aromatization and oestrogen-mediated pituitary growth hormone release. 
Non-aromatizable androgens increase growth rate in boys without altering serum GH/IGF-1, possibly 
via the androgen receptor in chondrocytes and local IGF-1 signalling in the growth plate.1, 82 Pubertal 
height velocity acceleration and subsequent growth plate closure seem to be absent in men with 
inactivating ERα mutations83 or aromatase deficiency84-87 who show steady, continues growth, 
suggesting that oestrogens have a dominant role in these processes. A recent study using ERαKO 
mice with no residual truncated isoforms confirmed the continuing longitudinal growth seen in the 
ERαKO (see next paragraph).88 The fact that 46,XY girls with complete androgen insensitivity 
syndrome have a growth spurt similar in timing and amplitude as 46,XX girls89 is probably due to 
oestrogen effects, but it does not exclude a role for AR itself. Male ARKO mice have been anecdotally 
noted to have increased femur length,90 but in men the effects of increased oestrogen due to 
aromatization probably override any possible direct effect of testosterone on the growth plate. On 
the other hand, further research on androgen regulation of (growth plate) chondrocytes would be of 
interest. 
 
4.2 Oestrogen deficiency: the primary mediator of bone loss in older hypogonadal men 
The primary role of oestrogens in postmenopausal osteoporosis was proposed by Fuller Albright in 
1941.91 Similarly, hypogonadal men with low T were noted to have increased risk of osteoporosis and 
fractures.92, 93 The historic dichotomous view that oestrogens were important for bone health in 
women and androgens in men was however challenged by a unique report of a man with an ERα 
mutation.83 He presented with tall stature, incomplete epiphyseal closure in adulthood and markedly 
decreased bone density. In 1998, investigators from the Mayo Clinic proposed a unitary model for the 
pathogenesis of osteoporosis with a central responsibility for oestrogens, not only in post-
menopausal but also in male osteoporosis and even in the negative calcium balance and secondary 
hyperparathyroidism in age-related osteoporosis.58 This was based on seminal observations,94 
subsequently confirmed in multiple prospective cohort studies, of a strong association between 
(calculated free or bioavailable) E2, bone turnover and bone density in community-dwelling men, 
whereas the same associations with T were variable, weak, absent or disappeared after correcting for 
E2 or other variables.95-105 On the other hand, threshold effects (i.e. greater decreases in serum E2 in 
women compared to relatively normal androgen levels in ageing men) probably limit the conclusions 
that can be drawn from such cohort studies. Indeed, in several studies, E2 (and SHBG, see below) 
have been associated with bone loss below a certain threshold,96, 101, 106 while this has not been 
confirmed in younger cohorts of men.105, 107 In the European Male Ageing Study (EMAS) of men aged 
40-79 years, the prevalence of T between 11 and 8 nmol/L was 12.9% while only 4.1% had T < 8 
nmol/L, showing that most hypogonadism is mild in cohort studies.108 Nevertheless, several 
complimentary lines of evidence (Box 1) confirm that oestrogens are crucial to restrain bone turnover 
in ageing men. Thus, the finding that T blocks orchidectomy-induced bone loss in ERαKO mice109 has 
been contradicted by human experiments,110 which is possibly due to limitations of the ERαKO mouse 
model (which shows high bone mass due to increased T, which also contrasts with the situation in an 
ERαKO man83). 111 112-114 115 84-87 116 117-119 120 121 110  
 
4.3 Low T and high SHBG pose additional risks 
The overall conclusion thus appears to be that oestrogens are more important than androgens in 
maintaining bone health in ageing men. Yet low testosterone and high SHBG may still harbour 
additional detriments. Free or bioavailable T has been associated with BMD (at predominantly 
cortical sites), bone area, muscle area and strength, reduced fat mass and hip, vertebral and non-
vertebral fractures in different large studies in older men.107, 122-124 Late-onset hypogonadism (LOH) as 
defined by the presence of three sexual symptoms according to criteria from the European Male 
Ageing Study (EMAS) appears to correlate more strongly than low T alone with low ultrasound-
estimated BMD.125 Similarly, risk for hip fractures has been found highest in men with both low E2 
and T.126 We have previously shown in mice that optimal effects of T require a functional AR.127 These 
data are in agreement with findings from a man with concomitant aromatase deficiency and low T, in 
whom T and E2 replacement showed additive effects.128 
In the largest study, low E2 and high SHBG were independent predictors of BMD losses and fracture 
risk in men, but risks were highest when both bioavailable E2 and T were combined with high 
SHBG.129, 130 SHBG has been associated independently of bioavailable T and E2 with improved cortical 
bone development in young men but accelerated bone losses with ageing and consequently 
increased fracture risk.106, 131-134 The mechanisms by which SHBG may influence bone in this 
apparently paradoxical manner require further investigation.135 
 
4.4 The role of catabolic enzymes 
Not only synthetic but also catabolic enzymes control steady state sex steroid serum levels. In the 
Swedish MrOS study, specific androgen metabolites correlated with male BMD, while T itself did 
not.102 Polymorphisms in the enzymes catechol-O-methyl-transferase (COMT, an oestrogen 
degrading enzyme) and uridine diphosphate glucuronosyltransferase 2B7 (which inactivates mainly 
androgens but also some oestrogens) have been associated with increased sex steroid levels and 
bone geometry in young men.136-139 In another large population-based study, the COMT 
polymorphism was independently associated with fracture risk but not BMD, and only in men.140 The 
activity of these and other steroid metabolizing enzymes, and whether they exert their influence 
mainly systemically or locally in bone, merits further study. 
4.5 The contribution of 5α-reductase type 1 
Only a small percentage of DHT enters the circulation, and this fraction does not correlate with male 
BMD.102 5α-reductase (encoded by Srd5a) type 2 is primarily expressed in male reproductive tissues 
including the prostate, whereas type 1 and 3 are expressed in many tissues including reproductive 
tissues and bone.141 The 5α-reductase inhibitor finasteride inhibits type 2 and 3 whereas dutasteride 
inhibits all three. It is therefore not unexpected that finasteride does not affect bone density, turn-
over, fracture risk or muscle anabolic effects of androgens.142-148 In contrast, male Srd5a1-/- mice have 
recently been characterized as having reduced bone mass and muscle strength despite normal 
androgen serum levels.149 Human RCTs however have not shown effects of dutasteride on bone 
metabolism,145, 150 nor does dutasteride influence the anabolic effects of testosterone on muscle.151 
Whether or not 5α-reductase type 1 activity contributes to male bone mass thus merits further 
investigation. 
Meanwhile, aromatizable androgens may be used preferentially to simultaneously compensate 
androgen and oestrogen deficiency in men with LOH. In a small randomized controlled trial (RCT), 
DHT gel treatment in older men with low T suppressed endogenous testosterone without affecting E2 
or BTMs,152 while another RCT showed decreased E2 as well as spinal BMD.153 Therefore, the main 
effect of androgens or selective AR modulators (SARMs) may depend on their suppression of 
oestrogens. We have previously shown in rodents that androgens and oestrogens apparently act via 
different pathways and that their combination might be beneficial compared to each strategy 
alone,154, 155 although this requires confirmation in men with LOH. 
 
5. RELATIVE CONTRIBUTIONS OF AR, ERα AND ERβ IN CORTICAL VS. TRABECULAR BONE 
Although observational studies in humans are important to determine the influence of sex steroids 
on male bone, the study of the respective contributions of AR and ER require knock-out animal 
models as well as confirmation in rare human genetic disorders. These studies have revealed 
unexpected complexity regarding the roles of these NRs in different bone compartments.26 
Both AR and ERα are required for optimal periosteal bone expansion,90, 156 although oestrogens limit 
periosteal expansion in early puberty, probably because of time-specific and independent effects on 
IGF-1.26, 81 For trabecular bone development on the other hand, AR is solely responsible.90, 156 Indeed, 
ARKO decreases cancellous bone, while systemic ERαKO increases it (probably due to increased 
androgen levels in this animal model109, 157) and combined AR/ERαKO does not decrease trabecular 
bone more than ARKO alone.90 Compared to wildtype females, male pubertal ARKO mice have equal 
length, decreased trabecular bone and identical cortical bone parameters, showing that androgens 
are required for optimal bone development, especially trabecular but also cortical, but not for 
longitudinal growth.158 These results are confirmed in humans: oestrogen therapy in young 
aromatase-deficient men indeed improves cortical thickness and area however without  increasing 
trabecular vBMD.86 Nevertheless, more recent animal studies using cell-specific ERαKO models do 
also suggest a role for ERα in trabecular bone formation (see below). ERβ plays a role in female bone 
health,157, 159, 160 but male ERßKO mice have normal bones and ERαßKO show no difference to ERαKO 
alone.154 
 
6. ACTION MECHANISMS OF AR AND ERα IN SPECIFIC BONE CELLS 
6.1 Androgens control osteoblasts and osteocytes, while oestrogens also regulate osteoclasts 
Cell culture experiments from ARKO mice have suggested that AR controls mainly osteoblasts and 
their indirect control of osteoclastogenesis.161 However, as mentioned above, global ARKO/ERKO 
models or gonadectomy/antagonist studies preclude definitive conclusions about the cellular targets 
of AR and ER in male bone. Indirect evidence suggested that AR and ER signalling targets mainly 
osteoblasts and osteoclasts, respectively. These assumptions have only recently been verified using 
Cre/LoxP mouse models, although this requires careful verification that neither the Cre driver nor the 
floxed genotypes have effects themselves (see Zajac et al. in this theme issue). 
6.1.1. AR in the osteoblast lineage 
Osteocalcin-Cre driven ARKO revealed that androgens stimulate mineralizing osteoblasts, thus 
indirectly inhibiting cortical and trabecular bone resorption, especially during times of bone 
accrual.162 Col2.3-Cre driven ARKO showed that mature osteoblasts contribute to trabecular bone 
maintenance.163 However, periosteal apposition was not influenced by AR deficiency in these mature 
cells, probably because the periosteum contains more pre- and proliferating osteoblasts. Indeed, AR 
overexpression in immature osteoblasts increases periosteal and decreases endosteal bone 
formation, whereas osteogenesis was inhibited at both envelopes following AR overexpression in 
mature osteoblasts.164, 165 Recently, we have shown in Dmp1-Cre mice that loss of AR in osteocytes 
results in similar, moderate impairment of trabecular bone maintenance.166 Importantly, AR 
expression increased with the maturation of osteoblasts towards osteocytes.166 These different 
phenotypes suggest that AR has a direct role across the entire osteoblast lineage. 
6.1.2. AR and ERα in osteoclasts 
Clearly, AR signalling has important indirect restraining effects on osteoclasts, for example by 
controlling cytokine production in bone marrow stromal cells.79 AR has been detected in vitro and 
with immunohistochemistry in rodent osteoclasts albeit at very low levels, and it may be absent in 
human osteoclasts.1, 167, 168 Several though not all studies have suggested that androgens also directly 
suppress in vitro osteoclast formation from haematopoietic precursors.1, 168-171 Although they could 
not confirm the presence of AR in osteoclasts, the group of Kato found to their surprise that 
cathepsin K-Cre-driven ARKO also induces bone resorption (although this data has only been 
published in abstract),172 in a similar way as they and others have reported for osteoclast-specific 
ERαKO in female (but not male) mice.173, 174 Thus, a direct in vivo role for AR in osteoclasts merits 
independent confirmation. 
6.1.3. ERα in osteoblasts 
ERα has recently been established to have a role in osteoblasts and osteocytes too. It was already 
known that osteoblast-specific overexpression of aromatase increases bone mass in male mice.175 
Prx1-Cre and Osterix-Cre mice have now been used to selectively excise ERα from pluripotent 
mesenchymal progenitors in the limb bud of the appendicular skeleton and, respectively, osteoblast 
progenitors. These mice showed mainly cortical bone deficits resulting from decreased periosteal 
bone formation, although cortical bone deficits were overcome during adulthood in Prx1-Cre ERαKO 
males.176 Deletion of ERα using the Col1a1 deleter did not affect cortical or trabecular bone. However, 
this should not be taken as evidence that ERα has no role downstream in osteoblast differentiation. 
Indeed, osteocalcin-Cre ERαKO decreased trabecular bone in males, and both trabecular and cortical 
bone in females.177 Dmp1-Cre ERαKO males also showed decreased bone formation and less 
trabecular bone, but there was no effect on cortical bone, or any effect in females. The authors 
concluded that the trabecular bone-sparing effects of oestrogens are mediated by osteocyte ERα in 
males, but probably by osteoclast ERα in females.178 Interestingly, both ERαKO179 and ARKO180 have 
been known to influence the response to mechanical loading, but the response to mechanical loading 
was unaltered in the respective osteocyte-specific knock-out mice.166, 178 
In summary, these studies in male mice suggest that both AR and ERα are required for optimal 
cortical bone expansion via actions in immature osteoblasts, and trabecular bone maintenance via 
actions in more differentiated osteoblasts and osteocytes (Figure 3). 
 
6.2 Indirect effects of AR and ER on bone via muscle, fat and the nervous system 
The interaction of bone with muscle, adipose and neural systems is increasingly studied. Tissue-
specific ARKO models are discussed in more detail in the accompanying review by Zajac et al. 
 
6.2.1. Bone-muscle interaction 
Male ARKO mice have impaired muscle development,181 and additional ERαKO further reduces 
muscle mass.90 However, muscle-specific ARKO mice did not show altered bone metabolism and only 
slightly reduced peripheral skeletal muscle mass, possibly because only perineal muscles display high 
AR content and androgen regulation in mice.182, 183 This contrasts with the well-known anabolic 
effects of androgens on human muscle.184 Thus, although the effects of androgens on bone in mice 
are unlikely to be mediated via the AR in muscle, it remains unclear whether sarcopenia in older men 
with LOH contributes directly or is merely associated with bone loss and fractures.2, 185, 186 
6.2.2. Bone-fat interaction 
Clinical evidence suggests a positive association between bone and fat, but mainly in females, 
possibly because adipocyte aromatase activity influences circulating E2 or increased gravitational 
loading.2, 185 Fat mass is principally regulated by oestrogens since double knockouts have similar 
adiposity compared to ERαKO alone,90 although androgens also have clear lipolytic activity, and male 
ARKO mice have increased adiposity.28 A link between glucose, insulin and bone metabolism has also 
been suggested in mice, and male bone metabolism is altered in diabetes and the metabolic 
syndrome. Thus, whether AR or ER signalling in adipocytes modulates sex steroid effects on bone 
would be of interest. 
6.2.3. Central nervous system control of bone mass 
Central nervous system regulation of bone mass has been demonstrated recently with often opposite 
effects to peripheral signalling. This also seems to be the case for oestrogens, since neuron-specific 
ERαKO using nestin-Cre increases bone formation via leptin.187 Conditional inactivation of AR in the 
nervous system of mice however disrupts the somatotropic axis as evidenced by growth retardation 
and twofold lower serum IGF-1, without relative differences in total bone mass or body 
composition.188 This reiterates that the skeletal sexual dimorphism resulting from sex steroids is 
dependent on indirect effects via growth hormone, IGF-1 and IGF binding proteins in brain, bone and 
liver.26, 81, 189 
 
7. CONCLUSIONS 
The musculoskeletal system is more robust in men, and sex steroid signalling remains essential for 
this sexual dimorphism. The advent of high resolution imaging has allowed better insights into the 
microarchitectural determinants of male bone strength. Specifically, androgens may promote 
trabecular bone development and thickness in young adulthood, as well as cortical consolidation in 
midlife and maintenance of cortical thickness and trabecular bone volume in older men by 
stimulating periosteal apposition and trabecular bone formation. Thus, although oestrogen deficiency 
is the primary mediator of hypogonadal bone loss in men, high SHBG and low T probably pose 
additional detriments. The role of sex steroid catabolic enzymes and local lipid metabolism within 
bone (e.g. by 5α reductase type 1) requires further investigation. Recent studies using knock-out 
mouse models have recently refined our understanding of the contributions of AR and ERα in 
osteoclasts, osteoblasts and osteocytes to cortical and trabecular bone development and 
maintenance. At the same time, they have reinforced the notion that sex steroids must have 
important pleiotropic effects on bone, e.g. via interaction with the nervous system, IGF-1 and altered 
response to mechanical loading. A better understanding of the microarchitectural, cellular and 
molecular mechanisms of actions of androgens and oestrogens continues to be necessary to develop 
therapeutic strategies which can exploit their benefits for bone health without unwanted side effects 
in other tissues.  
Acknowledgements 
M. Laurent and V. Dubois are research fellows of the Research Foundation Flanders. This work was 
supported by the Research Foundation Flanders via grants G.0858.11N and G.0684.12N, and 
OT/11/081 from KU Leuven. 
Competing Financial Interests 
Authors would declare that we have no financial or other competing interests 
 
8. REFERENCES 
1. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R et al. Androgens and 
bone. Endocr Rev 2004; 25: 389-425. 
2. Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: 
recent advances in pathophysiology and treatment. Best Pract Res Clin Endocrinol Metab 2013. 
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with 
osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33. 
4. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA et al. A systematic review of hip 
fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23: 2239-56. 
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A et al. Incidence and economic 
burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 
465-75. 
6. Tarride JE, Guo N, Hopkins R, Leslie WD, Morin S et al. The burden of illness of osteoporosis in 
Canadian men. J Bone Miner Res 2012; 27: 1830-8. 
7. Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD et al. The burden of illness of 
osteoporosis in Canada. Osteoporos Int 2012; 23: 2591-600. 
8. Frost M, Wraae K, Abrahamsen B, Hoiberg M, Hagen C et al. Osteoporosis and vertebral 
fractures in men aged 60-74 years. Age Ageing 2012; 41: 171-7. 
9. Nurmi-Luthje I, Sund R, Juntunen M, Luthje P. Post-hip fracture use of prescribed calcium plus 
vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: a 
nationwide study in Finland. J Bone Miner Res 2011; 26: 1845-53. 
10. Wastesson JW, Ringback Weitoft G, Parker MG, Johnell K. Educational level and use of 
osteoporosis drugs in elderly men and women: a Swedish nationwide register-based study. 
Osteoporos Int 2013; 24: 433-42. 
11. Curtis JR, McClure LA, Delzell E, Howard VJ, Orwoll E et al. Population-based fracture risk 
assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009; 24: 
956-62. 
12. Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, Cram P. Testing and treatment for 
osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 
2011; 22: 2973-80. 
13. Callewaert F, Boonen S, Vanderschueren D. Sex steroids and the male skeleton: a tale of two 
hormones. Trends Endocrinol Metab 2010; 21: 89-95. 
14. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z et al. FSH directly regulates bone mass. Cell 2006; 
125: 247-60. 
15. Zhu LL, Blair H, Cao J, Yuen T, Latif R et al. Blocking antibody to the beta-subunit of FSH 
prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci U 
S A 2012; 109: 14574-9. 
16. Yarram SJ, Perry MJ, Christopher TJ, Westby K, Brown NL et al. Luteinizing hormone receptor 
knockout (LuRKO) mice and transgenic human chorionic gonadotropin (hCG)-overexpressing mice 
(hCG alphabeta+) have bone phenotypes. Endocrinology 2003; 144: 3555-64. 
17. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ. Sex steroids, not FSH, influence 
bone mass. Cell 2006; 127: 1079; author reply 80-1. 
18. Allan CM, Kalak R, Dunstan CR, McTavish KJ, Zhou H et al. Follicle-stimulating hormone 
increases bone mass in female mice. Proc Natl Acad Sci U S A 2010; 107: 22629-34. 
19. Rouach V, Katzburg S, Koch Y, Stern N, Somjen D. Bone loss in ovariectomized rats: dominant 
role for estrogen but apparently not for FSH. J Cell Biochem 2011; 112: 128-37. 
20. Uihlein A, Kumbhani R, Siwila-Sackman E, Finkelstein J, Lee H et al. FSH Suppression in 
Eugonadal Men Does Not Change Bone Turnover Markers. J Bone Miner Res 2012; 27. 
21. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous 
steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J 
Clin Endocrinol Metab 1981; 53: 58-68. 
22. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. 
Endocr Rev 1989; 10: 232-74. 
23. Caldwell JD, Jirikowski GF. Sex hormone binding globulin and aging. Horm Metab Res 2009; 41: 
173-82. 
24. Helsen C, Kerkhofs S, Clinckemalie L, Spans L, Laurent M et al. Structural basis for nuclear 
hormone receptor DNA binding. Mol Cell Endocrinol 2012; 348: 411-7. 
25. Schauwaers K, De Gendt K, Saunders PT, Atanassova N, Haelens A et al. Loss of androgen 
receptor binding to selective androgen response elements causes a reproductive phenotype in a 
knockin mouse model. Proc Natl Acad Sci U S A 2007; 104: 4961-6. 
26. Callewaert F, Sinnesael M, Gielen E, Boonen S, Vanderschueren D. Skeletal sexual dimorphism: 
relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol 2010; 207: 127-
34. 
27. Ophoff J, Callewaert F, Venken K, De Gendt K, Ohlsson C et al. Physical activity in the androgen 
receptor knockout mouse: evidence for reversal of androgen deficiency on cancellous bone. Biochem 
Biophys Res Commun 2009; 378: 139-44. 
28. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD et al. Increased adiposity in DNA binding-
dependent androgen receptor knockout male mice associated with decreased voluntary activity and 
not insulin resistance. Am J Physiol Endocrinol Metab 2011; 301: E767-78. 
29. Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A et al. Osteoporosis and 
osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res 
Clin Endocrinol Metab 2008; 22: 765-85. 
30. Masud T, Binkley N, Boonen S, Hannan MT. Official Positions for FRAX(R) clinical regarding falls 
and frailty: can falls and frailty be used in FRAX(R)? From Joint Official Positions Development 
Conference of the International Society for Clinical Densitometry and International Osteoporosis 
Foundation on FRAX(R). J Clin Densitom 2011; 14: 194-204. 
31. Looker AC, Melton LJ, 3rd, Harris T, Borrud L, Shepherd J et al. Age, gender, and race/ethnic 
differences in total body and subregional bone density. Osteoporos Int 2009; 20: 1141-9. 
32. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women 
and men. Am J Epidemiol 1993; 137: 1203-11. 
33. Joakimsen RM, Fonnebo V, Magnus JH, Tollan A, Sogaard AJ. The Tromso Study: body height, 
body mass index and fractures. Osteoporos Int 1998; 8: 436-42. 
34. Bjornerem A, Bui Q, Ghasem-Zadeh A, Hopper J, Zebaze R et al. Fracture risk and height: An 
association partly accounted for by cortical porosity of relatively thinner cortices. J Bone Miner Res 
2013. 
35. Rudang R, Mellstrom D, Clark E, Ohlsson C, Lorentzon M. Advancing maternal age is associated 
with lower bone mineral density in young adult male offspring. Osteoporos Int 2011; 23: 475-82. 
36. Cooper C, Westlake S, Harvey N, Javaid K, Dennison E et al. Review: developmental origins of 
osteoporotic fracture. Osteoporos Int 2006; 17: 337-47. 
37. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak 
BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 
2003; 14: 843-7. 
38. Gafni RI, Baron J. Childhood bone mass acquisition and peak bone mass may not be important 
determinants of bone mass in late adulthood. Pediatrics 2007; 119 Suppl 2: S131-6. 
39. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 
8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res 2011; 26: 1729-39. 
40. Ohlsson C, Darelid A, Nilsson M, Melin J, Mellstrom D et al. Cortical consolidation due to 
increased mineralization and endosteal contraction in young adult men: a five-year longitudinal study. 
J Clin Endocrinol Metab 2011; 96: 2262-9. 
41. Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S et al. Peak bone mass from 
longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J 
Bone Miner Res 2010; 25: 1948-57. 
42. Darelid A, Ohlsson C, Nilsson M, Kindblom JM, Mellstrom D et al. Catch up in bone acquisition 
in young adult men with late normal puberty. J Bone Miner Res 2012; 27: 2198-207. 
43. Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Age- and gender-related 
differences in the geometric properties and biomechanical significance of intracortical porosity in the 
distal radius and tibia. J Bone Miner Res 2010; 25: 983-93. 
44. Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK. Age-related patterns of trabecular 
and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J 
Bone Miner Res 2011; 26: 50-62. 
45. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD. Low width of tubular bones is 
associated with increased risk of fragility fracture in elderly men--the MINOS study. Bone 2006; 38: 
595-602. 
46. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ et al. Effects of sex and age on bone 
microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone 
Miner Res 2006; 21: 124-31. 
47. Dalzell N, Kaptoge S, Morris N, Berthier A, Koller B et al. Bone micro-architecture and 
determinants of strength in the radius and tibia: age-related changes in a population-based study of 
normal adults measured with high-resolution pQCT. Osteoporos Int 2009; 20: 1683-94. 
48. Kirmani S, Christen D, van Lenthe GH, Fischer PR, Bouxsein ML et al. Bone structure at the 
distal radius during adolescent growth. J Bone Miner Res 2009; 24: 1033-42. 
49. Walsh JS, Paggiosi MA, Eastell R. Cortical consolidation of the radius and tibia in young men 
and women. J Clin Endocrinol Metab 2012; 97: 3342-8. 
50. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ et al. A population-based assessment of 
rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young 
adult women and men. J Bone Miner Res 2008; 23: 205-14. 
51. Lauretani F, Bandinelli S, Griswold ME, Maggio M, Semba R et al. Longitudinal changes in BMD 
and bone geometry in a population-based study. J Bone Miner Res 2008; 23: 400-8. 
52. Duan Y, Beck TJ, Wang XF, Seeman E. Structural and biomechanical basis of sexual dimorphism 
in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 2003; 18: 1766-74. 
53. Riggs BL, Melton Iii LJ, 3rd, Robb RA, Camp JJ, Atkinson EJ et al. Population-based study of age 
and sex differences in bone volumetric density, size, geometry, and structure at different skeletal 
sites. J Bone Miner Res 2004; 19: 1945-54. 
54. Szulc P, Seeman E. Thinking inside and outside the envelopes of bone: dedicated to PDD. 
Osteoporos Int 2009; 20: 1281-8. 
55. Szulc P, Boutroy S, Vilayphiou N, Chaitou A, Delmas PD et al. Cross-sectional analysis of the 
association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. 
J Bone Miner Res 2011; 26: 1358-67. 
56. Peacock M, Buckwalter KA, Persohn S, Hangartner TN, Econs MJ et al. Race and sex 
differences in bone mineral density and geometry at the femur. Bone 2009; 45: 218-25. 
57. Srinivasan B, Kopperdahl DL, Amin S, Atkinson EJ, Camp J et al. Relationship of femoral neck 
areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in 
men and women. Osteoporos Int 2011; 23: 155-62. 
58. Riggs BL, Khosla S, Melton LJ, 3rd. A unitary model for involutional osteoporosis: estrogen 
deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to 
bone loss in aging men. J Bone Miner Res 1998; 13: 763-73. 
59. Khosla S, Melton LJ, 3rd, Riggs BL. The unitary model for estrogen deficiency and the 
pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26: 441-51. 
60. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of 
the pathogenesis of osteoporosis. Endocr Rev 2010; 31: 266-300. 
61. Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD. Insulin-like growth factor I is a 
determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue 
Int 2004; 74: 322-9. 
62. Ohlsson C, Mellstrom D, Carlzon D, Orwoll E, Ljunggren O et al. Older men with low serum IGF-
1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res 2011; 26: 
865-72. 
63. Boonen S, Pye SR, O'Neill TW, Szulc P, Gielen E et al. Influence of bone remodelling rate on 
quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-
aged and elderly European men: the European Male Ageing Study (EMAS). Eur J Endocrinol 2011; 165: 
977-86. 
64. Pye SR, Almusalam B, Boonen S, Vanderschueren D, Borghs H et al. Influence of insulin-like 
growth factor binding protein (IGFBP)-1 and IGFBP-3 on bone health: results from the European Male 
Ageing Study. Calcif Tissue Int 2011; 88: 503-10. 
65. Curtis JR, Ewing SK, Bauer DC, Cauley JA, Cawthon PM et al. Association of intact parathyroid 
hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. J 
Clin Endocrinol Metab 2012; 97: 1937-44. 
66. Grundberg E, Lau EM, Pastinen T, Kindmark A, Nilsson O et al. Vitamin D receptor 3' 
haplotypes are unequally expressed in primary human bone cells and associated with increased 
fracture risk: the MrOS Study in Sweden and Hong Kong. J Bone Miner Res 2007; 22: 832-40. 
67. Vanderschueren D, Pye SR, O'Neill TW, Lee DM, Jans I et al. Active Vitamin D (1,25-
Dihydroxyvitamin D) and Bone Health in Middle-Aged and Elderly Men: The European Male Aging 
Study (EMAS). J Clin Endocrinol Metab 2013. 
68. Roef G, Lapauw B, Goemaere S, Zmierczak H, Fiers T et al. Thyroid hormone status within the 
physiological range affects bone mass and density in healthy men at the age of peak bone mass. Eur J 
Endocrinol 2011; 164: 1027-34. 
69. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM et al. A prospective study of 
thyroid function, bone loss, and fractures in older men: The MrOS study. J Bone Miner Res 2013; 28: 
472-9. 
70. Rolland T, Boutroy S, Vilayphiou N, Blaizot S, Chapurlat R et al. Poor trabecular 
microarchitecture at the distal radius in older men with increased concentration of high-sensitivity C-
reactive protein--the STRAMBO study. Calcif Tissue Int 2012; 90: 496-506. 
71. Roshandel D, Holliday KL, Pye SR, Boonen S, Borghs H et al. Genetic variation in the 
RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in 
men. J Bone Miner Res 2010; 25: 1830-8. 
72. Roshandel D, Holliday KL, Pye SR, Ward KA, Boonen S et al. Influence of polymorphisms in the 
RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the 
forearm in men. Calcif Tissue Int 2011; 89: 446-55. 
73. Roshandel D, Thomson W, Pye SR, Boonen S, Borghs H et al. Polymorphisms in genes involved 
in the NF-kappaB signalling pathway are associated with bone mineral density, geometry and 
turnover in men. PLoS One 2011; 6: e28031. 
74. Liu CT, Estrada K, Yerges-Armstrong LM, Amin N, Evangelou E et al. Assessment of gene-by-sex 
interaction effect on bone mineral density. J Bone Miner Res 2012; 27: 2051-64. 
75. Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F et al. Bone mass, bone 
geometry, and body composition in female-to-male transsexual persons after long-term cross-sex 
hormonal therapy. J Clin Endocrinol Metab 2012; 97: 2503-11. 
76. Taes Y, Lapauw B, Vandewalle S, Zmierczak H, Goemaere S et al. Estrogen-specific action on 
bone geometry and volumetric bone density: longitudinal observations in an adult with complete 
androgen insensitivity. Bone 2009; 45: 392-7. 
77. Han TS, Goswami D, Trikudanathan S, Creighton SM, Conway GS. Comparison of bone mineral 
density and body proportions between women with complete androgen insensitivity syndrome and 
women with gonadal dysgenesis. Eur J Endocrinol 2008; 159: 179-85. 
78. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA et al. Skeletal involution by age-
associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282: 27285-
97. 
79. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H et al. Regulation of interleukin-6, 
osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 
1995; 95: 2886-95. 
80. Hofbauer LC, Ten RM, Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit 
interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 
1999; 14: 1330-7. 
81. Callewaert F, Venken K, Kopchick JJ, Torcasio A, van Lenthe GH et al. Sexual dimorphism in 
cortical bone size and strength but not density is determined by independent and time-specific 
actions of sex steroids and IGF-1: evidence from pubertal mouse models. J Bone Miner Res 2010; 25: 
617-26. 
82. Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. 
Clin Endocrinol (Oxf) 2008; 68: 4-15. 
83. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM et al. Estrogen resistance caused by a 
mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-61. 
84. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S et al. Effect of testosterone and 
estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337: 91-5. 
85. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen 
therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599-603. 
86. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal 
periosteal bone expansion. J Clin Endocrinol Metab 2004; 89: 6025-9. 
87. Merlotti D, Gennari L, Stolakis K, Nuti R. Aromatase activity and bone loss in men. J 
Osteoporos 2011; 2011: 230671. 
88. Borjesson AE, Windahl SH, Karimian E, Eriksson EE, Lagerquist MK et al. The role of estrogen 
receptor-alpha and its activation function-1 for growth plate closure in female mice. Am J Physiol 
Endocrinol Metab 2012; 302: E1381-9. 
89. Zachmann M, Prader A, Sobel EH, Crigler JF, Jr., Ritzen EM et al. Pubertal growth in patients 
with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of 
girls. J Pediatr 1986; 108: 694-7. 
90. Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A et al. Differential regulation of bone 
and body composition in male mice with combined inactivation of androgen and estrogen receptor-
alpha. FASEB J 2009; 23: 232-40. 
91. Albright F, Smith PH, AM R. Postmenopausal osteoporosis. JAMA 1941; 116: 2465-74. 
92. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI et al. Osteoporosis in men 
with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106: 354-61. 
93. Swartz CM, Young MA. Male hypogonadism and bone fracture. N Engl J Med 1988; 318: 996. 
94. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M et al. Sex steroids and bone mass in 
older men. Positive associations with serum estrogens and negative associations with androgens. J 
Clin Invest 1997; 100: 1755-9. 
95. Khosla S, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM, Klee GG et al. Relationship of serum sex 
steroid levels and bone turnover markers with bone mineral density in men and women: a key role 
for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-74. 
96. Khosla S, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to 
longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 
3555-61. 
97. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F et al. Bioavailable estradiol may be an 
important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86: 
192-9. 
98. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B et al. Longitudinal association between 
sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88: 
5327-33. 
99. Szulc P, Uusi-Rasi K, Claustrat B, Marchand F, Beck TJ et al. Role of sex steroids in the 
regulation of bone morphology in men. The MINOS study. Osteoporos Int 2004; 15: 909-17. 
100. Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH et al. Endogenous sex 
hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men 
and women: the Rotterdam Study. J Clin Endocrinol Metab 2004; 89: 3261-9. 
101. Khosla S, Melton LJ, 3rd, Robb RA, Camp JJ, Atkinson EJ et al. Relationship of volumetric BMD 
and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 
2005; 20: 730-40. 
102. Vandenput L, Labrie F, Mellstrom D, Swanson C, Knutsson T et al. Serum levels of specific 
glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner 
Res 2007; 22: 220-7. 
103. Kuchuk NO, van Schoor NM, Pluijm SM, Smit JH, de Ronde W et al. The association of sex 
hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic 
fractures in older men and women. Clin Endocrinol (Oxf) 2007; 67: 295-303. 
104. Araujo AB, Travison TG, Leder BZ, McKinlay JB. Correlations between serum testosterone, 
estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J 
Clin Endocrinol Metab 2008; 93: 2135-41. 
105. Vanderschueren D, Pye SR, Venken K, Borghs H, Gaytant J et al. Gonadal sex steroid status and 
bone health in middle-aged and elderly European men. Osteoporos Int 2010; 21: 1331-9. 
106. Mellstrom D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M et al. Older men with low 
serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23: 
1552-60. 
107. Ward KA, Pye SR, Adams JE, Boonen S, Vanderschueren D et al. Influence of age and sex 
steroids on bone density and geometry in middle-aged and elderly European men. Osteoporos Int 
2011; 22: 1513-23. 
108. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ et al. Identification of late-onset hypogonadism 
in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35. 
109. Vandenput L, Ederveen AG, Erben RG, Stahr K, Swinnen JV et al. Testosterone prevents 
orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem Biophys Res 
Commun 2001; 285: 70-6. 
110. Yu E, Taylor A, Wulcyzn K, Webb M, Perros N et al. Hypogonadism with Estrogen Removal 
(HER): Differential Effects of Androgens and Estrogens on Bone Microarchitecture in Adult Men. 
Journal of Bone and Mineral Research 2012; 27: S66. 
111. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R et al. Evidence from the aged 
orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic 
agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002; 17: 2080-6. 
112. Limer KL, Pye SR, Thomson W, Boonen S, Borghs H et al. Genetic variation in sex hormone 
genes influences heel ultrasound parameters in middle-aged and elderly men: results from the 
European Male Aging Study (EMAS). J Bone Miner Res 2009; 24: 314-23. 
113. Holliday KL, Pye SR, Thomson W, Boonen S, Borghs H et al. The ESR1 (6q25) locus is associated 
with calcaneal ultrasound parameters and radial volumetric bone mineral density in European men. 
PLoS One 2011; 6: e22037. 
114. Huhtaniemi IT, Pye SR, Holliday KL, Thomson W, O'Neill TW et al. Effect of polymorphisms in 
selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in 
aging men. J Clin Endocrinol Metab 2010; 95: 1898-908. 
115. Huhtaniemi IT, Pye SR, Limer KL, Thomson W, O'Neill TW et al. Increased estrogen rather than 
decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin 
Endocrinol Metab 2009; 94: 277-84. 
116. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for 
prostate cancer. N Engl J Med 2005; 352: 154-64. 
117. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H et al. Bicalutamide monotherapy versus 
leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J 
Clin Oncol 2004; 22: 2546-53. 
118. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone 
mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 
171: 2272-6, quiz 435. 
119. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and 
predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with 
stratification of treatment based on presenting values. BJU Int 2009; 104: 800-5. 
120. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral 
density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009; 
94: 4785-92. 
121. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R et al. Relative contributions of 
testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin 
Invest 2000; 106: 1553-60. 
122. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M et al. Free testosterone is an 
independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner 
Res 2006; 21: 529-35. 
123. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM et al. Endogenous sex 
hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch 
Intern Med 2008; 168: 47-54. 
124. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable 
serum testosterone and estradiol and their relationships with muscle strength, bone density, and 
body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276-82. 
125. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR et al. Characteristics of androgen deficiency 
in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol 
Metab 2012; 97: 1508-16. 
126. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT et al. Estradiol, testosterone, and the risk 
for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119: 426-33. 
127. Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG et al. Role of the androgen 
receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J 
Bone Miner Res 2004; 19: 1462-70. 
128. Rochira V, Zirilli L, Madeo B, Aranda C, Caffagni G et al. Skeletal effects of long-term estrogen 
and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences 
of a priming effect of estrogen for sex steroids action on bone. Bone 2007; 40: 1662-8. 
129. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E et al. The effects of serum 
testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin 
Endocrinol Metab 2009; 94: 3337-46. 
130. Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE et al. Sex steroid hormones in older men: 
longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures 
in men study. J Clin Endocrinol Metab 2010; 95: 4314-23. 
131. Vanbillemont G, Lapauw B, Bogaert V, Goemaere S, Zmierczak HG et al. Sex hormone-binding 
globulin as an independent determinant of cortical bone status in men at the age of peak bone mass. 
J Clin Endocrinol Metab 2010; 95: 1579-86. 
132. Lorentzon M, Swanson C, Andersson N, Mellstrom D, Ohlsson C. Free testosterone is a 
positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: 
the GOOD study. J Bone Miner Res 2005; 20: 1334-41. 
133. Eriksson AL, Lorentzon M, Mellstrom D, Vandenput L, Swanson C et al. SHBG gene promoter 
polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and 
androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 2006; 91: 5029-37. 
134. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters and 
osteoporotic fractures in elderly men. J Bone Miner Res 2000; 15: 1405-11. 
135. Khosla S. Editorial: Sex hormone binding globulin: inhibitor or facilitator (or both) of sex 
steroid action? J Clin Endocrinol Metab 2006; 91: 4764-6. 
136. Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A et al. Sex steroid levels and cortical 
bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 
polymorphism (H268Y). J Clin Endocrinol Metab 2007; 92: 3697-704. 
137. Lorentzon M, Eriksson AL, Mellstrom D, Ohlsson C. The COMT val158met polymorphism is 
associated with peak BMD in men. J Bone Miner Res 2004; 19: 2005-11. 
138. Eriksson AL, Mellstrom D, Lorentzon M, Orwoll ES, Redlund-Johnell I et al. The COMT 
val158met polymorphism is associated with prevalent fractures in Swedish men. Bone 2008; 42: 107-
12. 
139. Lorentzon M, Eriksson AL, Nilsson S, Mellstrom D, Ohlsson C. Association between physical 
activity and BMD in young men is modulated by catechol-O-methyltransferase (COMT) genotype: the 
GOOD study. J Bone Miner Res 2007; 22: 1165-72. 
140. Stolk L, van Meurs JB, Jhamai M, Arp PP, van Leeuwen JP et al. The catechol-O-
methyltransferase Met158 low-activity allele and association with nonvertebral fracture risk in 
elderly men. J Clin Endocrinol Metab 2007; 92: 3206-12. 
141. Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE et al. Human osteoblast-like cells express 
predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab 2002; 87: 5401-7. 
142. Tollin SR, Rosen HN, Zurowski K, Saltzman B, Zeind AJ et al. Finasteride therapy does not alter 
bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. J Clin 
Endocrinol Metab 1996; 81: 1031-4. 
143. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J et al. The long-term effect of 
specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of 
a 4-year placebo controlled trial. J Urol 2002; 167: 2105-8. 
144. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD et al. Exogenous testosterone or 
testosterone with finasteride increases bone mineral density in older men with low serum 
testosterone. J Clin Endocrinol Metab 2004; 89: 503-10. 
145. Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ et al. The effect of 5alpha-
reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, 
hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 2008; 179: 
2333-8. 
146. Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-alpha reductase 
inhibition and risk of hip fracture. JAMA 2008; 300: 1660-4. 
147. Vestergaard P, Rejnmark L, Mosekilde L. Risk of fractures associated with treatment for benign 
prostate hyperplasia in men. Osteoporos Int 2011; 22: 731-7. 
148. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM et al. Exogenous testosterone (T) 
alone or with finasteride increases physical performance, grip strength, and lean body mass in older 
men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-10. 
149. Windahl SH, Andersson N, Borjesson AE, Swanson C, Svensson J et al. Reduced bone mass and 
muscle strength in male 5alpha-reductase type 1 inactivated mice. PLoS One 2011; 6: e21402. 
150. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride 
in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-8. 
151. Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M et al. Effect of testosterone 
supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with 
suppressed testosterone production: a randomized controlled trial. JAMA 2012; 307: 931-9. 
152. Meier C, Liu PY, Ly LP, de Winter-Modzelewski J, Jimenez M et al. Recombinant human 
chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis 
in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004; 89: 3033-41. 
153. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L et al. Long-term effects of 
dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate 
disease: a randomized, placebo-controlled trial. Ann Intern Med 2010; 153: 621-32. 
154. Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S et al. Differential effects on bone of 
estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc 
Natl Acad Sci U S A 2003; 100: 13573-8. 
155. Tivesten A, Moverare-Skrtic S, Chagin A, Venken K, Salmon P et al. Additive protective effects 
of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res 
2004; 19: 1833-9. 
156. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R et al. Relative impact of androgen and 
estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing 
male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 2006; 21: 576-
85. 
157. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D et al. Deletion of estrogen receptors 
reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. 
Bone 2002; 30: 18-25. 
158. MacLean HE, Moore AJ, Sastra SA, Morris HA, Ghasem-Zadeh A et al. DNA-binding-dependent 
androgen receptor signaling contributes to gender differences and has physiological actions in males 
and females. J Endocrinol 2010; 206: 93-103. 
159. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral 
content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999; 
104: 895-901. 
160. Sims NA, Clement-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M et al. A functional 
androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol 
receptor-deficient mice. J Clin Invest 2003; 111: 1319-27. 
161. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K et al. Suppressive function of androgen 
receptor in bone resorption. Proc Natl Acad Sci U S A 2003; 100: 9416-21. 
162. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A et al. Mineralization and bone 
resorption are regulated by the androgen receptor in male mice. J Bone Miner Res 2009; 24: 621-31. 
163. Notini AJ, McManus JF, Moore A, Bouxsein M, Jimenez M et al. Osteoblast deletion of exon 3 
of the androgen receptor gene results in trabecular bone loss in adult male mice. J Bone Miner Res 
2007; 22: 347-56. 
164. Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA et al. Targeted overexpression of 
androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. 
Endocrinology 2004; 145: 3507-22. 
165. Wiren KM, Semirale AA, Zhang XW, Woo A, Tommasini SM et al. Targeting of androgen 
receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model 
for compartment-specific androgen action in the skeleton. Bone 2008; 43: 440-51. 
166. Sinnesael M, Claessens F, Laurent M, Dubois V, Boonen S et al. Androgen receptor (AR) in 
osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR 
disruption in mouse osteocytes. J Bone Miner Res 2012; 27: 2535-43. 
167. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in 
human bone. J Clin Endocrinol Metab 1997; 82: 3493-7. 
168. Turner AG, Notini AJ, Chiu WSM, Hodge J, Nicholson G et al. Androgen receptor expression 
and function in osteoclasts. Open Physiol J 2008; 1. 
169. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM et al. Androgens suppress 
osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 
2001; 142: 3800-8. 
170. Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC et al. Androgens regulate bone 
resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999; 96: 505-10. 
171. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different 
cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005; 20: 
2224-32. 
172. Nakamura T, Watanabe T, Nakamichi Y, Fukuda T, Matsumoto T et al. Genetic evidence of 
androgen receptor function in osteoclasts: generation and characterization of osteoclast-specific 
androgen receptor knockout mice. J Bone Miner Res 2004; 19: S3. 
173. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K et al. Estrogen prevents bone loss via 
estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-23. 
174. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H et al. The estrogen receptor-alpha in 
osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol 
Endocrinol 2010; 24: 323-34. 
175. Sjogren K, Lagerquist M, Moverare-Skrtic S, Andersson N, Windahl SH et al. Elevated 
aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J 
Bone Miner Res 2009; 24: 1263-70. 
176. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L et al. Estrogen receptor-alpha signaling 
in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest 2013; 123: 394-404. 
177. Maatta JA, Buki KG, Gu G, Alanne MH, Vaaraniemi J et al. Inactivation of estrogen receptor 
alpha in bone-forming cells induces bone loss in female mice. FASEB J 2013; 27: 478-88. 
178. Windahl SH, Borjesson AE, Farman HH, Engdahl C, Moverare-Skrtic S et al. Estrogen receptor-
alpha in osteocytes is important for trabecular bone formation in male mice. Proc Natl Acad Sci U S A 
2013; 110: 2294-9. 
179. Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L. Endocrinology: bone adaptation requires 
oestrogen receptor-alpha. Nature 2003; 424: 389. 
180. Callewaert F, Bakker A, Schrooten J, Van Meerbeek B, Verhoeven G et al. Androgen receptor 
disruption increases the osteogenic response to mechanical loading in male mice. J Bone Miner Res 
2010; 25: 124-31. 
181. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA et al. Impaired skeletal muscle 
development and function in male, but not female, genomic androgen receptor knockout mice. 
FASEB J 2008; 22: 2676-89. 
182. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K et al. Androgen signaling in 
myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle 
strength or fatigue. Endocrinology 2009; 150: 3558-66. 
183. Chambon C, Duteil D, Vignaud A, Ferry A, Messaddeq N et al. Myocytic androgen receptor 
controls the strength but not the mass of limb muscles. Proc Natl Acad Sci U S A 2010; 107: 14327-32. 
184. Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F. Androgens and skeletal 
muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 
2012; 69: 1651-67. 
185. Gielen E, Verschueren S, O'Neill TW, Pye SR, O'Connell MD et al. Musculoskeletal frailty: a 
geriatric syndrome at the core of fracture occurrence in older age. Calcif Tissue Int 2012; 91: 161-77. 
186. Verschueren S, Gielen E, O'Neill TW, Pye SR, Adams JE et al. Sarcopenia and its relationship 
with bone mineral density in middle-aged and elderly European men. Osteoporos Int 2013; 24: 87-98. 
187. Ohlsson C, Engdahl C, Borjesson AE, Windahl SH, Studer E et al. Estrogen receptor-alpha 
expression in neuronal cells affects bone mass. Proc Natl Acad Sci U S A 2012; 109: 983-8. 
188. Raskin K, de Gendt K, Duittoz A, Liere P, Verhoeven G et al. Conditional inactivation of 
androgen receptor gene in the nervous system: effects on male behavioral and neuroendocrine 
responses. J Neurosci 2009; 29: 4461-70. 
189. Olson LE, Ohlsson C, Mohan S. The role of GH/IGF-I-mediated mechanisms in sex differences 
in cortical bone size in mice. Calcif Tissue Int 2011; 88: 1-8. 
 
 
Box 1. Evidence supporting the primary role of oestrogens in bone loss in older men 
Animal models:  
- E2 is a more effective bone-sparing agent than DHT in aged male rats111  
Human genetic evidence:  
- polymorphisms in ER (but not AR) signalling negatively influence male bone112-114  
- longer CAG repeats diminish AR function but may be compensated by increased T levels, 
paradoxically stimulating bone via aromatization115  
- men with aromatase deficiency have high T but suboptimal bone mass which improves with 
oestrogen (but not androgen) therapy84-87 
Human observational studies: 
- several large cohort studies confirm relationship between E2 and male bone metabolism, 
while the same relationship with T is weak, absent or disappears after correcting for E2 (but 
not vice versa) 
- increased bone turnover and fracture risk in older men receiving androgen deprivation 
therapy for prostate cancer116 may be due to a loss of substrate for aromatization, since AR 
antagonists alone are not detrimental for bone117-119  
Human experiments: 
- aromatase inhibition in older men increases T but decreases E2 and BMD120  
- gonadotropin inhibition and T or E2 add-back shows that E2 has the dominant antiresorptive 
effect121  
- T replacement with or without aromatase inhibition demonstrates that T alone cannot 
overcome male bone resorption in the absence of E2110  
 
Figure 1. Structural determinants of bone strength in men based on high resolution peripheral 
computed tomography (HR-pqCT) at the ultradistal radius. Adapted, with permission, from Khosla et 
al [46]. 
 
Figure 2. Schematic model of bone geometry changes at the tibia during adult lifespan in men and 
women. When comparing young women and men, men have greater cortical thickness due to 
greater periosteal perimeter (shown in black), while women mainly decrease their endocortical 
perimeter (also shown in black). With ageing, cortical thinning results from endocortical bone 
resorption in both genders (difference compared to age 20 shown in blue), but this is much more 
pronounced in women, and ongoing periosteal apposition (difference compared to age 20 shown in 
red) in both genders is unable to compensate for the differences. On the other hand, bone is placed 
further away from the central axis in men at all ages, and this dramatically improves biomechanics. 
Adapted, with permission, based on data from Lauretani et al [51]. 
 
Figure 3. Schematic illustration of the cellular targets of AR and ERα on periosteal, endocortical and 
trabecular surfaces in male mice. Based on a µCT image of the proximal murine tibia. 
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Figure 3 
AR 
Periosteal apposition:
Increased through actions in
immature osteoblasts164
Endosteal bone formation:
Decreased through actions in 
immature and mature osteoblasts164,165
Endosteal bone resorption: 
decreased during puberty through actions in 
mineralizing osteoblasts162
Trabecular bone formation:
Maintained through actions in early164 and 
differentiated osteoblasts162,163,165 and 
osteocytes166
ERα
Periosteal apposition:
Increased through actions in
immature osteoblasts176
Trabecular bone formation:
Maintained through actions in mineralizing
osteoblasts177 and osteocytes178
(Trabecular bone resorption:
Inhibited by osteoclast ERα in females, but
unaffected by actions in osteoclasts in male 
mice173)
 
